Intradermal Botulinum Toxin A Injection Versus Topical 2% Glycopyrrolate for the Treatment of Primary Facial Hyperhidrosis: A Pilot Study and Review of Literature.
Journal
Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
ISSN: 1524-4725
Titre abrégé: Dermatol Surg
Pays: United States
ID NLM: 9504371
Informations de publication
Date de publication:
01 08 2022
01 08 2022
Historique:
pubmed:
3
8
2022
medline:
5
8
2022
entrez:
2
8
2022
Statut:
ppublish
Résumé
Facial hyperhidrosis (HH), a common problem with both cosmetic and psychological impact, interferes with quality of life. Wide range of treatment options is available for HH. Finding the most effective and yet a safe, tolerable option is the main target. To evaluate and compare clinical efficacy, safety, and tolerability of topical 2% glycopyrrolate versus intradermal Botulinum toxin A injection in facial HH treatment. Twenty-four patients with primary facial HH were randomly divided into 2 equal groups: Group A included patients treated by intradermal Botulinum toxin A injection and Group B included patients treated by topical glycopyrrolate gel 2%. Starch iodine test was performed before and after treatment to assess response, along with Hyperhidrosis Disease Severity Scale, Dermatology Life Quality Index (DLQI), and patient satisfaction. Both modalities showed complete response in 75% of cases with a longer duration of action in botulinum toxin group up to 6 months. Side effects were minor and temporary. Both Hyperhidrosis Disease Severity Scale and DLQI showed statistically significant improvement after treatment. Topical glycopyrrolate 2% showed comparable results to Botulinum toxin A in facial HH treatment with faster onset but shorter duration of action.
Sections du résumé
BACKGROUND
Facial hyperhidrosis (HH), a common problem with both cosmetic and psychological impact, interferes with quality of life. Wide range of treatment options is available for HH. Finding the most effective and yet a safe, tolerable option is the main target.
OBJECTIVE
To evaluate and compare clinical efficacy, safety, and tolerability of topical 2% glycopyrrolate versus intradermal Botulinum toxin A injection in facial HH treatment.
MATERIALS AND METHODS
Twenty-four patients with primary facial HH were randomly divided into 2 equal groups: Group A included patients treated by intradermal Botulinum toxin A injection and Group B included patients treated by topical glycopyrrolate gel 2%. Starch iodine test was performed before and after treatment to assess response, along with Hyperhidrosis Disease Severity Scale, Dermatology Life Quality Index (DLQI), and patient satisfaction.
RESULTS
Both modalities showed complete response in 75% of cases with a longer duration of action in botulinum toxin group up to 6 months. Side effects were minor and temporary. Both Hyperhidrosis Disease Severity Scale and DLQI showed statistically significant improvement after treatment.
CONCLUSION
Topical glycopyrrolate 2% showed comparable results to Botulinum toxin A in facial HH treatment with faster onset but shorter duration of action.
Identifiants
pubmed: 35917265
doi: 10.1097/DSS.0000000000003490
pii: 00042728-202208000-00009
doi:
Substances chimiques
Botulinum Toxins, Type A
EC 3.4.24.69
Glycopyrrolate
V92SO9WP2I
Types de publication
Journal Article
Review
Comment
Langues
eng
Sous-ensembles de citation
IM
Pagination
843-848Commentaires et corrections
Type : CommentOn
Informations de copyright
Copyright © 2022 by the American Society for Dermatologic Surgery, Inc. Published by Wolters Kluwer Health, Inc. All rights reserved.
Références
Garcia-Souto F, Del Boz J, Colmenero-Sendra M, Polo-Padillo J. Craniofacial hyperhidrosis: clinical characteristics and response to treatment in a cohort of 97 patients treated with oral oxybutynin. Dermatol Ther 2021;34:e14658.
Walling HW. Clinical differentiation of primary from secondary hyperhidrosis. J Am Acad Dermatol 2011;64:690–5.
Haider A, Solish N. Focal hyperhidrosis: diagnosis and management. CMAJ 2005,172:69–75.
Kim WO, Kil HK, Yoon KB, Noh K. Botulinum toxin: a treatment for compensatory hyperhidrosis in the trunk. Dermatol Surg 2009;35:833–8.
Kinkelin I, Hund M, Naumann M, Hamm H. Effective treatment of frontal hyperhidrosis with botulinum toxin A. Br J Dermatol 2000;143:824–7.
Kim WO, Kil HK, Yoon KB, Yoon DM. Topical glycopyrrolate for patients with facial hyperhidrosis. Br J Dermatol 2008;158:1094–7.
Hornberger J, Grimes K, Naumann M, Glaser DA, et al. Multi-speciality working group on the recognition, diagnosis and treatment of primary focal hyperhidrosis. J Am Acad Dermatol 2004;51:274–86.
George SM, Atkinson LR, Farrant PB, Shergill BS. Botulinum toxin for focal hyperhidrosis of the face. Br J Dermatol 2014;170:211–3.
Lowe NJ, Yamauchi PS, Lask GP, Patnaik R, et al. Efficacy and safety of botulinum toxin type A in the treatment of palmer hyperhidrosis: a double blinded, randomized, placebo controlled study. Dermatol Surg 2002;28:822–7.
Cabreus P, Swartling C, Rystedt A. Postmenopausal craniofacial hyperhidrosis treated with botulinum toxin type B. J Dermatol 2019;46:874–8.
Karlqvist M, Rosell K, Rystedt A, Hymnelius K, et al. Botulinum toxin B in the treatment of craniofacial hyperhidrosis. J Eur Acad Dermatol Venereol 2014;28:1313–7.
Bourne RB, Chesworth BM, Davis AM, Mahomed NN, et al. Patient satisfaction after total knee arthroplasty: who is satisfied and who is not? Clin Orthop Relat Res 2010;468:57–63.
McConaghy JR, Fosselman D. Hyperhidrosis: management options. Am Fam Physician 2018;97:729–34.
Nicholas R, Quddus A, Baker D. Treatment of craniofacial hyperhidrosis: a systemic review. Am J Clin Dermatol 2015;16:361–70.
De Paiva A, Meunier FA, Molgo J, Aoki K, et al. Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci USA 1999;96:3200–5.
Boger A, Herath H, Rompel R, Ferbert A. Botulinum toxin for treatment of craniofacial hyperhidrosis. J Neurol 2000;247:857–61.
Schulze-Bonhage A, Schroder M, Ferbert A. Botulinum toxin in the therapy of gustatory sweating. J Neurol 1996;243:143–6.
Drobik C, Laskawi R, Schwab S. Therapy of Frey syndrome with botulinum toxin A. Experiences with a new method of treatment. HNO 1995;43:644–8.
Komericki P, Ardjomand N. Hyperhidrosis of face and scalp: repeated successful treatment with botulinum toxin type A. Indian J Dermatol Venereol Leprol 2012;78:201–202.
Hyun MY, Son IP, Lee Y, Choi HG, et al. Efficacy and safety of topical glycopyrrolate in patients with facial hyperhidrosis: a randomized, multicentre, double‐blinded, placebo‐controlled, split‐face study. J Eur Acad Dermatol Venereol 2015;29:278–82.